Letters to the Editor
Risks of H. pylori “Test-and-Treat” Strategy in Dyspepsia
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2008 Jan 15;77(2):146.
to the editor: We read with interest the article, “Update on Helicobacter pylori Treatment” in the February 1, 2007, issue of American Family Physician.1 The authors give the “test-and-treat” strategy in the evaluation of patients with dyspepsia an evidence rating of A, stating that it reduces the use of endoscopies and antisecretory medications. This strategy will indeed reduce the number of endoscopies—at the cost of an increase in antibiotic prescriptions. Seventy-five percent of these prescriptions will be unnecessary, because only one out of every four treated patients will have peptic ulcers and thus benefit from antibiotic therapy.2 Therefore, the statement could instead be made that the “test-and-treat” strategy will lead to unnecessary antibiotic treatment in 75 percent of patients with dyspepsia.
The test-and-treat strategy risks unnecessary allergic reactions, antibiotic-associated diarrhea, and the development of antibiotic resistance. Assuming a prevalence of dyspepsia of about 25 percent in the adult U.S. population, with a yearly incidence of 7 percent,3,4 and a prevalence of H. pylori seropositivity ranging from 20 percent in younger patients to 50 percent in 45 to 55-year-olds,2 millions of unnecessary antibiotics would be prescribed every year. This would counteract the successful efforts to reduce antibiotic prescriptions for otitis media, bronchitis, and other viral infections.
Author disclosure: Nothing to disclose.
1. Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007;75(3):351–358.
2. Moore RA. Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective. Oxford, 1994. http://www.jr2.ox.ac.uk/bandolier/bandopubs/hpyl/hpall.html. Accessed September 5, 2007.
3. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989;298(6665):30–32.
4. Talley NJ, Fett SL, Zinsmeister AR, Mellon L J 3d. Gastrointestinal tract symptoms and self-reported abuse: a population-based study Gastroenterology. 1994;107(4):1040–49.
editor's note: This letter was sent to the authors of “Update on Helicobacter pylori Treatment,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions